Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Stevanato Group
STVN
Stevanato Group
Rising Regulatory Costs And Local Rivalry Will Compress Margins
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 10 Analysts
Published
19 Jun 25
Updated
09 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$23.00
1.7% undervalued
intrinsic discount
09 Aug
US$22.62
Loading
1Y
15.1%
7D
0.1%
Author's Valuation
US$23.0
1.7% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$23.0
1.7% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
1b
2019
2021
2023
2025
2027
2028
Revenue €1.4b
Earnings €240.1m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
8.35%
Life Sciences revenue growth rate
0.32%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
9.88%
Calculation
€240.14m
Earnings '28
x
29.74x
PE Ratio '28
=
€7.14b
Market Cap '28
€7.14b
Market Cap '28
/
273.38m
No. shares '28
=
€26.12
Share Price '28
€26.12
Share Price '28
Discounted to 2025 @ 9.81% p.a.
=
€19.73
Fair Value '25
€19.73
Fair Value '25
Converted to USD @ 1.1643 EUR/USD Exchange Rate
=
US$22.97
Fair Value '25